Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 6/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 12/20 | 0.37 |
| ▸ | PPARA | Q07869 | 10/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2000521 | 0.92 | PPARA (0.41) | PPARGPPARA | |
| SCHEMBL1383663 | 0.89 | PPARA (0.43) | PPARGPPARA | |
| SCHEMBL2000348 | 0.83 | PPARD (0.53) | NR1I2PPARA | |
| SCHEMBL2006292 | 0.79 | PPARA (0.41) | NR1I2PPARGPPARA | |
| SCHEMBL2001143 | 0.78 | NR1I2 (0.36) | NR1I2PPARGPPARA | |
| SCHEMBL2005443 | 0.78 | PPARG (0.39) | NR1I2PPARGPPARA | |
| SCHEMBL2000618 | 0.78 | PPARD (0.58) | PPARA | |
| SCHEMBL12568527 | 0.77 | S1PR5 (0.42) | S1PR5S1PR3S1PR1PPARGPPARA | |
| SCHEMBL2001195 | 0.77 | PPARA (0.50) | NR1I2PPARGPPARA | |
| SCHEMBL2003247 | 0.74 | PPARD (0.60) | PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | MA XIN | 2009-12-03 | — | — | US | disclosed |
| US-7592361-B2 | (5-{3-[4-(4,5,6,7-tetrahydro-benzooxazol-2-yl)-phenoxy]-propoxy}-indol-1-yl)-acetic acid; diabetes, obesity, hyperlipidemia, and atherosclerotic disease | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20060264486-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | IDO1, IDO2, AADAT | S1PR5 637/4885S1PR3 921/4885S1PR1 1149/4885 |
| US-20060264486-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | IDO1, IDO2, AADAT | S1PR5 637/4885S1PR3 921/4885S1PR1 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.